Bandaranayake, Rajintha M., Prabu-Jeyabalan, Moses, Kakizawa, Junko, Sugiura, Wataru, Schiffer, Celia A.
The effect of amino acid variability between human immunodeficiency virus type 1 (HIV-1) clades on structure and the emergence of resistance mutations in HIV-1 protease has become an area of...
Foulkes-Murzycki, Jennifer E., Prabu-Jeyabalan, Moses, Cooper, Deyna, Henderson, Gavin J., Harris, Janera, Swanstrom, Ronald I., ...
Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or functional constraints at specific residues within the viral protease....
Prabu-Jeyabalan, Moses, King, Nancy M., Nalivaika, Ellen A., Heilek-Snyder, Gabrielle, Cammack, Nick, Schiffer, Celia A.
In our previous crystallographic studies of human immunodeficiency virus type 1 (HIV-1) protease-substrate complexes, we described a conserved "envelope" that appears to be important for substrate...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Romano, Keith, Schiffer, Celia A.
Human immunodeficiency virus type 1 (HIV-1) protease processes and cleaves the Gag and Gag-Pol polyproteins, allowing viral maturation, and therefore is an important target for antiviral therapy....
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Maturation of human immunodeficiency virus (HIV) depends on the processing of Gag and Pol polyproteins by the viral protease, making this enzyme a prime target for anti-HIV therapy. Among the...
King, Nancy M., Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., De Bethune, Marie-Pierre, Schiffer, Celia A.
TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt) and multidrug-resistant (MDR) viruses in vitro as well as in...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant...
Liu, Hui, Radhakrishnan, Padhma, Magoun, Loranne, Prabu-Jeyabalan, Moses, Campellone, Kenneth Geno, Savage, Pamela Joyce, ...
Attachment to host cells by enterohaemorrhagic Escherichia coli (EHEC) is associated with the formation of a highly organized cytoskeletal structure containing filamentous actin, termed an attaching...
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease (2002)
King, Nancy M., Melnick, Laurence, Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Yang, Shiow-Shong, Gao, Yun, ...
The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to...
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease (2002)
King, Nancy M., Melnick, Laurence, Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Yang, Shiow-Shong, Gao, Yun, ...
The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant...
King, Nancy M., Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Wigerinck, Piet, De Béthune, Marie-Pierre, Schiffer, Celia A.
TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt) and multidrug-resistant (MDR) viruses in vitro as well as in...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Maturation of human immunodeficiency virus (HIV) depends on the processing of Gag and Pol polyproteins by the viral protease, making this enzyme a prime target for anti-HIV therapy. Among the...
Prabu-Jeyabalan, Moses, King, Nancy M., Nalivaika, Ellen A., Heilek-Snyder, Gabrielle, Cammack, Nick, Schiffer, Celia A.
In our previous crystallographic studies of human immunodeficiency virus type 1 (HIV-1) protease-substrate complexes, we described a conserved “envelope” that appears to be important for...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Romano, Keith, Schiffer, Celia A.
Human immunodeficiency virus type 1 (HIV-1) protease processes and cleaves the Gag and Gag-Pol polyproteins, allowing viral maturation, and therefore is an important target for antiviral therapy....
Foulkes, Jennifer E., Prabu-Jeyabalan, Moses, Cooper, Deyna, Henderson, Gavin J., Harris, Janera, Swanstrom, Ronald, ...
Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or functional constraints at specific residues within the viral protease....
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant...
King, Nancy M., Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Wigerinck, Piet, De Béthune, Marie-Pierre, Schiffer, Celia A.
TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt) and multidrug-resistant (MDR) viruses in vitro as well as in...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Maturation of human immunodeficiency virus (HIV) depends on the processing of Gag and Pol polyproteins by the viral protease, making this enzyme a prime target for anti-HIV therapy. Among the...
Prabu-Jeyabalan, Moses, King, Nancy M., Nalivaika, Ellen A., Heilek-Snyder, Gabrielle, Cammack, Nick, Schiffer, Celia A.
In our previous crystallographic studies of human immunodeficiency virus type 1 (HIV-1) protease-substrate complexes, we described a conserved “envelope” that appears to be important for...
Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Romano, Keith, Schiffer, Celia A.
Human immunodeficiency virus type 1 (HIV-1) protease processes and cleaves the Gag and Gag-Pol polyproteins, allowing viral maturation, and therefore is an important target for antiviral therapy....
Foulkes, Jennifer E., Prabu-Jeyabalan, Moses, Cooper, Deyna, Henderson, Gavin J., Harris, Janera, Swanstrom, Ronald, ...
Sequence variability associated with human immunodeficiency virus type 1 (HIV-1) is useful for inferring structural and/or functional constraints at specific residues within the viral protease....
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease
King, Nancy M., Melnick, Laurence, Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., Yang, Shiow-Shong, Gao, Yun, ...
The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to...
Bandaranayake, Rajintha M., Prabu-Jeyabalan, Moses, Kakizawa, Junko, Sugiura, Wataru, Schiffer, Celia A.
The effect of amino acid variability between human immunodeficiency virus type 1 (HIV-1) clades on structure and the emergence of resistance mutations in HIV-1 protease has become an area of...